抗人白血病细胞分化抗原的单克隆抗体：与大鼠白血病的交叉反应及对大鼠白血病的体内抑制作用

Monoclonal antibody against a differentiation antigen on human leukemia cells: cross-reactivity with rat leukemia and suppression of rat leukemia in vivo.

作者信息

Johnson R J, Shin H S

出版信息

J Immunol. 1983 Jun;130(6):2930-6.

Abstract

We produced a McAb against a normal differentiation antigen on human ANLL that cross-reacts with a rat ANLL. The McAb reacted with all ANLL cells tested as well as normal undifferentiated myelomonocytic cells. This McAb, of the IgM isotype, in the presence of C mediated lysis of human and rat leukemic cells in vitro. In addition, it mediated complete tumor suppression in rats engrafted with 10(2) to 10(3) rat leukemic cells in vivo. No significant side effects were observed in McAb-treated rats. McAb of this type may be useful in the treatment of human ANLL after conventional therapy, which often eliminates most leukemic cells, leaving a small number of residual cells. The ultimate utility of this McAb for human therapy or McAb directed against the same or other differentiation antigens remains to be determined.

摘要

我们制备了一种针对人急性非淋巴细胞白血病（ANLL）正常分化抗原的单克隆抗体（McAb），它与大鼠ANLL存在交叉反应。该McAb与所有检测的ANLL细胞以及正常未分化的骨髓单核细胞发生反应。这种IgM同种型的McAb在补体（C）存在的情况下，可在体外介导人源和大鼠白血病细胞的裂解。此外，它在体内可介导对移植了10²至10³个大鼠白血病细胞的大鼠的肿瘤完全抑制。在接受McAb治疗的大鼠中未观察到明显的副作用。这类McAb可能在常规治疗后对人ANLL的治疗有用，常规治疗通常会消除大多数白血病细胞，仅留下少量残留细胞。这种McAb用于人类治疗的最终效用或针对相同或其他分化抗原的McAb的效用仍有待确定。